Your Cart

Imagion Biosystems Investor Update

Imagion Biosystems Investor Update

Imagion Biosystems is pleased to provide an update on its capital management and progress towards its first-in-human study,
Read the Investor Update.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.